Pyxis Oncology (NASDAQ:PYXS) Given Buy Rating at HC Wainwright

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $7.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 392.96% from the company’s current price.

Several other brokerages have also commented on PYXS. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Royal Bank Of Canada dropped their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. Finally, Stephens increased their price target on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Pyxis Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.20.

Pyxis Oncology Stock Down 3.4%

Shares of NASDAQ PYXS opened at $1.42 on Tuesday. The company has a market capitalization of $88.41 million, a PE ratio of -0.89 and a beta of 1.45. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The firm has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $2.52.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Tuesday, March 24th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.06. The firm had revenue of $11.04 million for the quarter. As a group, equities analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP boosted its holdings in Pyxis Oncology by 37.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock worth $58,000 after acquiring an additional 13,550 shares in the last quarter. HRT Financial LP increased its holdings in shares of Pyxis Oncology by 157.5% during the fourth quarter. HRT Financial LP now owns 39,649 shares of the company’s stock valued at $45,000 after acquiring an additional 24,251 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Pyxis Oncology during the second quarter worth approximately $40,000. LPL Financial LLC lifted its holdings in shares of Pyxis Oncology by 150.7% in the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after purchasing an additional 21,100 shares in the last quarter. Finally, Engineers Gate Manager LP bought a new position in shares of Pyxis Oncology in the 4th quarter worth $26,000. 39.09% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.